Nycomed Group A/S, PharmaPlan Pty. Ltd., Recordati deal

Nycomed's Nycomed S.p.A. subsidiary received a license to co-market Recordati's silodosin in Italy to treat the signs and symptoms of benign prostatic hyperplasia (BPH). Separately, PharmaPlan received exclusive rights to market silodosin in South Africa. Recordati submitted an MAA for silodosin last November, with a decision expected in 1H10. Financial terms of the deals were not disclosed. ...